Braveheart Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BRVE | SLDB | EWTX | KARD | CYTK | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 1.83B | 719.48M | 4.18B | 1.34B | 8.73B | 1.78B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -10.2 | -3.9 | -21.2 | -4.9 | -14.1 | -6.3 |
| Price/book | -1.6 | 1.9 | 9.2 | 2.2 | -50.2 | 145.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −31.68% | +14.31% | +165.53% | −33.32% | +2.88% | −29.11% |
| Today | +1.70% | −2.33% | −1.56% | −2.18% | −0.19% | −2.24% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BRVE news ›Braveheart Bio (NASDAQ:BRVE) Stock Jumps 8.1% - Still a Buy?
Shares of Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) traded up 8.1% on Thursday. The stock traded as high as $21.44 and last traded at $21.84. Approximately 80,989 shares traded hands during mid-day trading, a decline of 83% from…
Braveheart Bio Shares Climb 5.50% as Its Phase 3 Heart Drug Trial Rapidly Gains Momentum Following Its IPO
Braveheart Bio shares rose 5.5% after the company began its pivotal Phase 3 trial of BHB-1893 and reported financial results supporting development of two late-stage programmes.
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
ibtimes.com.au1
-
marketbeat.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.